| 翻訳と辞書 |
Apremilast
Apremilast (brand name Otezla) is an orally available small molecule inhibitor of phosphodiesterase 4 (PDE4). Apremilast specifically inhibits PDE4 and inhibits spontaneous production of TNF-alpha from human rheumatoid synovial cells.〔(Apremilast )〕 It has anti-inflammatory activity.
==Medical use==
Apremilast was approved by the United States Food and Drug Administration in March 2014 for treatment of adults with active psoriatic arthritis.〔(FDA approves Otezla to treat psoriatic arthritis )〕 Apremilast is the first oral agent that is FDA-approved for the treatment of psoriatic arthritis and offers the convenience of oral dosing compared to treatment with biopharmaceuticals.〔(Apremilast for the Treatment of Psoriatic Arthritis ) American College of Rheumatology (14 June 2014). Retrieved 29 October 2014.〕 In September 2014, the US FDA approved Otezla (apremilast) for the treatment of moderate to severe plaque psoriasis.〔("Oral Otezla (apremilast) Approved by the U.S. Food and Drug Administration for the Treatment of Patients with Moderate to Severe Plaque Psoriasis" ) (Press release). Celgene Corporation. 23 September 2014. Retrieved 29 October 2014.〕 It is also being tested for its efficacy in treating other chronic inflammatory diseases such as ankylosing spondylitis, Behcet's disease,〔http://www.nejm.org/doi/full/10.1056/NEJMoa1408684#t=articleBackground〕 and rheumatoid arthritis. Celgene reported seven kinds of crystal form A,B,C,D,E,F, and G and thought the crystal form B was the most thermodynamically stable anhydrous form. However, Utopharm company reported another more thermodynamically stable anhydrous crystal form II than the crystal form B.〔http://www.utopharm.com/youchuo_en/news_sub.aspx?id=61〕
抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』
■ウィキペディアで「Apremilast」の詳細全文を読む
スポンサード リンク
| 翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|